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Background: One of the most important steps for procedural success of transcatheter closure of ASD is the appropriate devise size selection. In 
this regard, the controversy still exists on necessity or accuracy of current balloon sizing technique (stop-flow technique) in patients with large (>30 
mm) defect. The purpose of study was to evaluate the clinical efficacy of live 3 dimensional transesophageal echocardiography (TEE) for detecting 
the accurate maximum diameter of large ASD.
Patients and Methods: Since 2005, a total of 330 patients have been undergone of catheter closure of ASD, of which 32 patients having >30 
mm ASD device implantations were enrolled in this study. Balloon sizing was used in the first 8 patients, and device was selected as the same 
diameter of balloon sizing. In remaining 24 patients, balloon sizing was not indicated; device was selected +4 mm larger than maximum diameter 
of defect which was measured by live 3 dimensional TEE. If maximum diameter was >35 mm, a 38 mm device was selected. Appropriate device 
selection was judged by lateral or LAO projection at the time of catheterization by independent evaluators for this procedure.
Results: Median age at procedure was 56 years (ranged from 9 to 82), Qp/Qs was 2.6 (2.0 to 4.1), and ASD diameter was 31.5 (26 to 38) mm. 
Amplatzer Septal Occluder was used in all procedures, the median diameter of device was 34 (30 to 38) mm. There were no significant differences 
about patient’s profile between the first 8 patients and remaining 24 patients. Selected device was judged as “oversized” in 3 patients among 
the first 8 patients, however no patients in remaining. In 2 of 3 patients who were judged as “oversized”, device was exchanged to 4 mm smaller 
sized device. No hemodynamic and device-associated complications, device migration, cardiac erosion were observed during the follow-up period 
(median 15.2 months).
Conclusions: Even if appropriate balloon sizing using stop-flow technique was performed, over-sizing device selection could not be avoided 
especially in patients with large defect. Measurement of accurate maximum diameter using live 3 dimensional TEE is valuable and can contribute to 
appropriate device selection in this patient’s group.
